Urogen Pharma (NASDAQ:URGN) Share Price Breaks Below Two Hundred Day Moving Average on Disappointing Earnings

Shares of Urogen Pharma (NASDAQ:URGN) passed below its 200-day moving average during trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock has a 200-day moving average of $31.46 and traded as low as $27.55. Urogen Pharma shares last traded at $28.74, with a volume of 2,897,423 shares traded.

The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14). The business had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million.

Key Headlines Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% sequentially. The company also said repeat prescribers made up 50% of ZUSDURI writers, suggesting growing adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 PDUFA goal date, providing a regulatory milestone for the next-generation therapy. UroGen also reported that the first patient was dosed in its UGN-501 Phase 1 trial. UroGen Q3 2026 results and highlights
• Negative Sentiment: UroGen cut its FY2026 guidance, a key source of investor concern. Although ZUSDURI sales were strong, reported quarterly revenue of $89 million was slightly below the cited $89.92 million consensus, and earnings coverage characterized the results as missing estimates. The company reported a loss of $0.03 per share; estimate comparisons varied across reports. UroGen stock falls on Q3 results and guidance cut

Analyst Ratings Changes

URGN has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Urogen Pharma in a report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Guggenheim increased their target price on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $52.38.

Insider Activity

In other Urogen Pharma news, General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the sale, the general counsel owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total transaction of $37,383.32. Following the transaction, the insider owned 59,882 shares of the company’s stock, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 65,269 shares of company stock worth $3,037,646 in the last quarter. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

Several large investors have recently bought and sold shares of the stock. Sterling Capital Management LLC grew its position in Urogen Pharma by 442.1% in the 3rd quarter. Sterling Capital Management LLC now owns 1,339 shares of the company’s stock worth $54,000 after purchasing an additional 1,092 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Urogen Pharma by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company’s stock worth $361,000 after buying an additional 1,165 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $66,000. Quantbot Technologies LP bought a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Urogen Pharma in the 3rd quarter worth approximately $101,000. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Stock Performance

The stock has a market cap of $1.40 billion, a PE ratio of -14.52 and a beta of 1.68. The business has a 50 day moving average price of $39.60 and a two-hundred day moving average price of $31.46.

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.